Since our results above demonstrated that T cells play an important role in A2-APM anti-GBM efficacy, next we investigated which subtype of T cells (CD4 or CD8) plays a dominant role in A2-APM antitumor therapy. The gene discussed is CD8A; the disease is glioblastoma.